which company owns retatrutide Eli Lilly just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% 🎙️ NEW EPISODE: Retatrutide—The Triple

almost none can repair loss of muscles

Macrophage membrane-mimetic nanoparticles also utilize their natural inflammatory chemotactic ability to effectively target damaged kidneys

Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial

Patients with prespecified postbaseline eye procedures (panretinal photocoagulation for proliferative or severe nonproliferative diabetic retinopathy, local photocoagulation for new vessels, and vitrectomy for diabetic retinopathy) were also considered as 3-step progressors regardless of actual change in ETDRS score from baseline

The effect of myofascial release in patients with breast cancer-related lymphedema: a cross-over randomized controlled trial